Nutra Pharma Corp., a biotechnology holding company that owns rights to patents and intellectual property related to the development of drugs for HIV and Multiple Sclerosis has announced today that its majority owned subsidiary, Infectech, Inc. (Pink Sheets:IFEC - News), received a matching funds grant through a research proposal at Ohio State University.
Dr. Srinand Sreevatsan of the Food Animal Health Research Program of Ohio State University was chosen by the OARDC (Ohio Agricultural Research and Development Center) competitive grants program for the funding of his proposal entitled Assessment of the use of Paraffin Baiting for Diagnostic of the Johne's Disease Pathogen, Mycobacterium avium subspecies paratuberculosis (MAP). Infectech, Inc. owns the patents, which Dr. Sreevatsan is utilizing for his approved grant. Mycobacteria are responsible worldwide for billions of dollars in damage annually to the cattle industry. Specifically, Mycobacterium avium is a leading cause of disease in AIDS patients worldwide. The Infectech technology will allow for a more rapid and efficient detection and treatment of this pathogen.
"This grant will allow for some important validation of Infectech's patented technology," commented Dr. Mitchell Felder, Chief Executive Officer for Infectech. "Third-party validation in commercially-viable applications should rapidly move our technology through the FDA approval process and into the marketplace."
Infectech owns 29 issued patents related to the rapid isolation, growth, identification and antibiotic sensitivity of disease causing bacteria such as Tuberculosis ("TB") and Mycobacterium avium-intracellulare ("MAI"). Infectech's researchers discovered that certain grades of paraffin wax, when used in conjunction with a microscope slide, and combined with a nutrient broth, provides for the rapid isolation, growth and identification of various disease causing bacteria. Infectech has developed a diagnostic test kit based on this technology. The basic test kit consists of a glass slide coated with paraffin, which is used as a carbon (food) source by certain pathogenic bacterial species such as TB. The slides are incubated in a sample of almost any bodily fluid (a non-invasive sample of saliva is preferred) within a nutrient broth. This creates a semi-solid growth medium for the bacteria, which imitates its natural environment within a human or animal host. The bacteria collect on the paraffin slide in 4-8 days. Testing can then be done to identify the species of bacteria. This testing can be done via acid-fast staining or through PCR gene amplification. Additionally, the bacteria can be cultured with antibiotics to test for specific sensitivities. Through the choice of different nutrient broths, each kit can be tailored to encourage the growth of a specific bacterium. The test kits are being designed to work on a class of bacteria that includes TB, MAI, Para-tuberculosis, Pseudomonas and Nocardia.
"We are very excited about the opportunity to have researchers from Ohio State University work with this technology," said Rik Deitsch, Nutra Pharma's Chief Executive Officer. "They have a proven track record in microbiology research that will go a long way in helping Infectech gain regulatory approval, bringing the Company to revenues in the near future," he added.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The matching funds grant at Ohio State University should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.